(Q36222932)

English

Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeuti

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeuti (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

multicenter clinical trial

0 references

0 references

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

15

object named as

Ka F To

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Charles Erlichman

20

object named as

Charles Erlichman

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1 reference

ORCID Public Data File 2021

author name string

Winnie Yeo

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Hyun C Chung

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Stephen L Chan

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Ling Z Wang

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Robert Lim

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Joel Picus

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Michael Boyer

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Frankie K F Mo

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Jane Koh

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sun Y Rha

10

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Edwin P Hui

11

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Hei C Jeung

12

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Jae K Roh

13

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Simon C H Yu

14

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Qian Tao

16

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Brigette B Ma

17

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Anthony W H Chan

18

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Joanna H M Tong

19

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Anthony T C Chan

21

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Boon C Goh

22

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

20 August 2012

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

30

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

27

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

3361-3367

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Clinical studies of histone deacetylase inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Dose escalation methods in phase I cancer clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Epigenetics provides a new generation of oncogenes and tumour-suppressor genes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Histone deacetylase inhibitors for treatment of hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Aberrant Promoter Methylation Profiles of Tumor Suppressor Genes in Hepatocellular Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

Basic principles of ROC analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

1 October 2017

A sensitive and specific liquid chromatography–tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

22 September 2018

Epigenetic modifiers: basic understanding and clinical development.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

22 September 2018

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

22 September 2018

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

22 September 2018

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

22 September 2018

Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

22 September 2018

Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

22 September 2018

The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438233

22 September 2018

HDAC inhibitors and cardiac safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/22915658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22915658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2011.41.2395

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36222932&oldid=2143281113"